Clinical laboratory evaluations of aprepitant for the treatment of opioid depende

阿瑞吡坦治疗阿片类药物依赖的临床实验室评价

• 批准号: 8104238
• 负责人: Stephen Ross
• 金额: $ 36.57万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8104238
• 关键词: Acute; Attenuated; Behavioral; Behavioral Model; Characteristics; Choice Behavior; Clinical; Cues; Drug Metabolic Detoxication; Evaluation; Genetic Polymorphism; Heroin; Laboratories; Modeling; Morphine; Naloxone; Opiate Addiction; Opioid; Patients; Pharmaceutical Preparations; Pharmacogenetics; Psychological reinforcement; Receptor Gene; Rewards; Stress; Testing; Therapeutic; Withdrawal; aprepitant; base; behavior test; craving; disorder later incidence prevention; drug craving; experience; mu opioid receptors; opioid withdrawal; preclinical study; psychologic; receptor; response

Project Summary Current treatments for opioid dependence would benefit by the addition of a non-opioid based treatment medication. Recent pre-clinical studies have demonstrated the involvement of the NK1 rector in opioid reward and withdrawal. This study proposes to investigate a clinically available the NK1 antagonist, aprepitant, in opioid dependent patients. Based on the unique behavioral and pharmacological characteristics of opioid addiction, and what is known of the currently employed treatments, we propose that the therapeutic mechanism of any potential opioid addiction treatment medication must include the ability to reduce opioid withdrawal. This is of particular importance during treatment initiation (eg. detoxification). In addition, for longterm treatment and relapse prevention it is important to manage drug craving, to ameliorate the effects of stress, and inhibit the rewarding effects of opioids if patients do experience a slip. Therefore, we propose to study aprepitant in the clinical laboratory, using models of acute opioid reward, reinforcement and withdrawal, as well as stress- and cue-exposure responding.

项目摘要 目前对阿片依赖的治疗将受益于添加非阿片类药物 治疗药物。最近的临床前研究表明，NK1参与了 阿片类药物奖励和戒断方面的校长。这项研究建议研究一种临床上可用的 NK1拮抗剂，在阿片依赖患者中出现。基于独特的行为和 阿片成瘾的药理学特点及目前已知的情况 通过治疗，我们认为任何潜在的阿片类药物的治疗机制 成瘾治疗药物必须包括减少阿片类药物戒断的能力。这是 在治疗开始期间特别重要(例如，解毒)。此外，从长远来看， 治疗和预防复发重要的是管理药物渴求，改善疗效 缓解压力，并抑制阿片类药物的回报效应，如果患者确实经历了滑倒。因此， 我们建议在临床实验室中使用急性阿片类药物奖励模型来研究阿片类药物， 强化和撤退，以及压力和线索暴露的反应。